About us
Revolutionizing Immunotherapy
Treos Bio is a clinical stage company introducing a disruptive computational techology to change the paradigm of cancer immunotherapy development by resolving the dual challenges of patient and tumor heterogeneity. We use proprietary therapeutic peptides, produced through commercially scalable processes without need for tumor biopsy, to stimulate clinically effective cancer-specific immune responses in patients predicted by our diagnostic tests to respond.
Key figures
>100k
tumors in proprietary database
19
solid tumor indications
84%
precision
3
clinical trials completed
$45m
equity financing raised
Leadership & Board of Directors
Sunjeet Sawhney
-
Mr. Sawhney is Chief Executive Officer of Treos Bio, bringing over 25 years of global biopharmaceutical leadership across biotech and large pharma, spanning discovery, clinical development, commercialization, and corporate strategy. Prior to joining Treos Bio, he served as Chief Executive Officer and Board Member of Rappta Therapeutics, where he advanced a first-in-class oncology asset through IND-enabling development and secured a landmark out-licensing transaction in 2025. Earlier, Mr. Sawhney was Senior Vice President and Global Oncology Franchise Head at Ipsen, responsible for a $1.2 billion portfolio and global business development strategy. He has held senior international leadership roles at Clovis Oncology (VP / General Manager, International), Baxalta (Managing Director, UK & Ireland), and Novartis Oncology, where over 13 years he progressed through senior commercial and medical positions across the UK, Italy, and Switzerland. He began his pharmaceutical career in medical affairs and clinical research at Roche, Sanofi, and Chiltern.
A board-trained leader, Mr. Sawhney combines a scientific foundation with strong commercial and operational acumen, having built and led high-performing organizations across more than 30 countries. He holds an MSc in Immunology of Infectious Diseases from the London School of Hygiene & Tropical Medicine (University of London) and a BSc (Hons) in Genetics from Queen Mary University of London. He completed the Board Directors Programme in Organizational Leadership at Henley Business School.
Chief Executive Officer
Enikő R. Tőke, Ph.D.
-
Dr. Enikő Tőke is a Co-Founder of Treos Bio and co-inventor of all Treos Bio proprietary patents. She brings more than 20 years of interdisciplinary experience in translational biomedical research, with a particular focus on the development of immunotherapies across oncology, infectious diseases and allergy.
Dr. Tőke has played a central scientific role in the discovery and development of novel active immunotherapy platforms, including Langerhans cell-targeting immunotherapies, advanced nanomedicine delivery systems, pharmaceutically acceptable polymer technologies (novel excipients), and medical devices. Multiple programs originating from her research have progressed into clinical-stage drug development.
She is the lead author of numerous peer-reviewed scientific publications and is a regular presenter at international scientific conferences. Her work spans early discovery through clinical development, bridging academic innovation and industry execution.
Dr. Tőke holds a PhD from the Budapest University of Technology and Economics (Hungary) and an MSc in Biochemical Engineering from Babes-Bolyai University, Cluj-Napoca (Romania)
Chief Scientific Officer, Director
Gábor Illés
-
Mr. Illés was one of the first investors in Treos Bio. Having served as a non-executive director from inception, he joined Treos as Chief Financial Officer in 2018. Mr Illés has over 25 years of experience in technology investments and corporate finance. He was a founding partner of BXR Partners LLP, the in-house investment advisory arm of BXR Group, a leading international private investment group, prior to which he had a ten-year career in investment banking with Credit Suisse First Boston in London.
A British and Hungarian citizen, Mr. Illés holds a M.Sc. degree in Business Administration (First Class Hons) from Corvinus University, Budapest and a CEMS Master degree in International Management.
Chief Financial Officer, Director
Hagop Youssoufian, M.D.
-
Dr. Youssoufian is a physician-scientist with more than 25 years of experience in drug development working with seed-stage ventures to multi-national biotech and pharmaceutical corporations. After a successful academic career as a clinician, teacher and NIH-funded investigator, he held increasingly senior roles in clinical and translational science at Bristol-Myers Squibb (Head of Experimental Medicine), Sanofi Aventis (Distinguished Scientist), ImClone (CMO), Ziopharm Oncology (President of R&D and CMO), Progenics (EVP of R&D), and BIND (CMO). He supported or led the development and approval of a number of medicines including Sprycel, Taxotere, Erbitux, Cyramza, Lartruvo and Copiktra. He is an elected member of the American Society for Clinical Investigation, the recipient of many national and international awards, and the author of more than 100 publications. He received a B.S. in biology from Boston College and M.Sc./M.D. from University of Massachusetts Medical School, followed by fellowships at Johns Hopkins, Harvard and MIT.
Chair of Medical Strategy
Levente Molnár
-
Mr. Molnár is a programmer and mathematician with more than 20 years of experience in bioinformatics and data mining on large databases. His IT team at Treos has developed algorithms to transform genetic sequence information to immunological maps, for digital antigen design and for genotype based cancer specific prognostic risk calculator. Additionally, he has experience with electronic laboratory and clinical trial management systems, as well as electronic regulatory documentation systems. Mr. Molnár is a graduate of Eötvös Loránd University, Faculty of Science, Budapest, Hungary (MsC).
Linkedin
Head of Bioinformatics
John Hautman, JD
-
As an attorney and entrepreneur, Mr. Hautman has advised technology companies in the areas of general corporate, venture capital, intellectual property protection, technology commercialization and licensing for more than 35 years. Mr. Hautman was previously a senior partner and a co-leader of the worldwide Intellectual Property Practice for the international law firm Hogan & Hartson (now Hogan Lovells) and was recognized in 2003 by Virginia Business as one of the Legal Elite of Virginia lawyers. Mr. Hautman is a graduate of the University of Virginia Law School, USA (JD), Xavier University, Cincinnati, USA (AB Summa Cum Laude) and Le Sorbonne, Paris, France (DS).
Chief Legal Officer
Christopher C. Gallen, M.D., Ph.D.
-
Dr. Gallen trained initially in Philosophy (University of Florida) then trained as a Medical Scientist (M.D., Ph.D., Emory), psychiatrist (Stanford) and neurologist (UCSD) then led an innovative career as an academician (The Scripps Research Institute) where his laboratory with great collaborators pioneered the use of Magnetic Source Imaging developing the first clinical indications for the technology, made important scientific discoveries (including the first demonstration of human cerebral plasticity and of the 40 Hz current in man) and acted as a scientific spokesman supporting the NADAQ IPO of BTi. Dr. Gallen then joined Quintiles, rising to Sr. Medical Director, where he drove pivotal trials of several therapeutics that became registered for CNS and other disorders.
Dr. Gallen then became President of the nascent Premier Research Worldwide (PRWW) and with great staff innovated the first use of Remote Data Capture into the Clinical Research Organization (CRO) field, (an approach now circa >95% of CRO data handling globally), introduced Computer Assisted Research and Development (CARD) into clinical research, played a key role in developing the therapeutic that became XYREMTM led PRWW to become a public company through a NASDAQ IPO then grew the company to international status. Dr. Gallen then joined Pharmacia as VP Medical Research where he led CNS development and/or registration of several therapeutics, managed clinical operations for all therapeutic areas in the Americas, played a leadership role in the successful re-engineering of Pharmacia clinical and was promoted to Site Head R&D for the Kalamazoo site.
Dr. Gallen next became VP Clinical Operations at Wyeth where, enabled by great staff and collaborators, he led a transformative reorganization that produced top tier industry performance, created the Alliance for Clinical Excellence (ACE) with Accenture (the first large scale industry movement into use of India for data management), and developed what emerged as the Functional Services Model for managing out-sourcing, now one of the main industry models globally. Dr. Gallen next became CEO of Vancouver-based Neuromed, negotiated a large collaboration with Merck, in-licensed OROS-hydromorphone from Alza, took Neuromed public becoming CEO of Combinatorx and later, as head of R&D, registered EXALGO™. Prior to joining WEX Pharmaceuticals Inc. as CEO, Dr. Gallen was CEO of SK Biopharmaceuticals, the first Western CEO of a major Korean pharmaceutical company, led its fine staff in significant advancement – moving important therapeutics into successful late stage trials and guided the successful re-focusing of its Custom Manufacturing Business.
Chairman, Non-executive Director
Peter Kadas
-
Peter Kadas is a senior adviser to BXR Partners LLP. He founded and led Credit Suisse First Boston Budapest from 1989 to 1995. In 1995 he co-founded Renaissance Capital in Moscow before moving to MC Securities in London in 1996. From 1997 to 2000 he was CEO of Croesus Central European Corporate Restructuring Fund which he co-founded.
Mr. Kadas then worked in various roles in the UK arm of a predecessor of the BXR Group until 2010. He joined BXR Partners LLP in November 2010 and holds a number of non-executive directorships in BXR Group companies. A British and Canadian citizen, he has a degree in Economics and Politics from the University of Toronto and an MBA from Dartmouth College.
Through the Kadas Family Charitable Foundation, he and his wife Gyongyver Kadas have chosen important causes worldwide, particularly educational institutions and including Dartmouth College, University of Toronto, Oxford University, the London School of Economics and Haifa University. Furthermore, Mr. Kadas is founder and director of the Kadas Prize Foundation, which, working with partners at Cambridge University, CRASSH (the Centre for Research in the Arts, Social Sciences and Humanities) and Cambridge University Press, funds the Nine Dots Prize, an innovative book prize for creative thinking that tackles contemporary societal issues.
Non-executive Director
Isabel Fox
-
Isabel Fox is an early stage deep-tech investor, mother, wellness coach and horse breeder. She is Head of Investor Relations at Hoxton Ventures and former Head of Third Party Funds at Molten Ventures.
She was one of just a handful of female partners in the UK when she founded Outsized Ventures, an early stage deep-tech fund, and invested $80m into ground-breaking founders who are daring to disrupt the status quo and improve the world we live in. She joined our Board of Directors in 2021 when Outsized Ventures led a $14 million investment round into Treos Bio.
Prior to Outsized, Isabel founded two corporate communications firms focused on the venture ecosystem in London, New York and San Francisco. She also co-founded two software start-ups (one exit) and was an active angel investor in the UK and US, before moving into LP positions in emerging managers with the potential for Alpha.
Throughout her career, she has been enormously supportive of women working in her industry – and, for 15 years, played an active role mentoring up and coming female talent.
Isabel sits on the Innovate UK Council (equivalent to DARPA in the US) and supports the commercialization of the UK’s best research and science. She has a strong global network and has worked in New York, San Francisco, Singapore and London.
She holds a B.S. in Economic and Social History from the University of Exeter.
Non-executive Director
Ruti Alon
-
Ms. Alon currently serves as a Board Member for Vascular Biogenics (VBLT), Phoska Biopharma Pte Ltd., BlueTree Ltd and Moringa Acquisition Corp (MACAU), in addition to serving as a Chairperson for BrainsGate. Previously, Ms. Alon was a General Partner at Pitango Venture Capital, the largest venture capital fund in Israel, where she established and led investments in the life sciences sector and served as a Board member and Chair for multiple companies ultimately acquired by top innovators in the industry. Earlier in her career, Ms. Alon was a Senior Healthcare Analyst on Wall Street, where she held positions of increasing responsibility at both Montgomery Securities and Kidder Peabody. Ms. Alon is the co-founder of several leading non-profit organizations to advance the technological and life sciences ecosystem in Israel, including a Covid-19 relief fund. Ms. Alon received a B.A. in Economics at the Hebrew University, Jerusalem, a M.Sc. at Columbia School of Physicians & Surgeons and an M.B.A. with a focus in Finance at Boston University.
Non-executive Director
Daniel Hallgarten
-
Daniel Hallgarten is a partner of BXR Advisory Partners LLP, an adviser to the BXR group, an international investment group, and leads HGT Management LLP, a multi-family office.
Following a degree in chemistry from the University of Nottingham and a year in research (natural product synthesis), Daniel trained as a chartered accountant specialising in tax with Arthur Andersen & Co. in London and Brussels. He spent ten years as an investment banker first at S.G.Warburg in London and Madrid and, following two years at the European Investment Fund in Luxembourg, UBS Investment Bank in London where he specialised in the telecoms sector. Before working for a predecessor of BXR Advisory Partners, he spent two years helping to run a small software company which was deploying big data and artificial intelligence solutions in the telecom fraud detection space.
He is a non-executive director of Marex Spectron Group (a commodity futures broker) and Food Freshness Technology Holdings (a food technology company) and is a trustee of The Badur Foundation and the Kadas Prize Foundation. He has an honorary doctorate in law from the University of Nottingham.
As well as advising clients with biotech investments, he is also an investor in early-stage biotech companies in his private capacity.
Non-executive Director
Clinical Advisory Board
Hans-Joachim Schmoll, M.D.
-
Prof. Schmoll is one the most relevant medical oncologist in Germany, an exceptional leader who influenced the development of oncology. He has educated generations of oncologist in Germany and many other countries and chaired several consensus conferences leading to new treatment guidelines. As editor of the German Standard Refence Book for Medical and Multidisciplinary Oncology, he defined over the last 30 years the treatment standards and education in oncology in German speaking countries.
Prof. Schmoll has been a key clinical researcher who investigated oncology drugs in numerous clinical trials, mostly within the European Organization for Research and Treatment of Cancer (EORTC), Arbeitsgemeinschaft Internistische Onkologie (AIO) and other large international cooperation. His research focused to germ-cell and colorectal cancers, where he defined worldwide standards for the management of patients. His publications have exceptionally high citation rate of eg. 1500-1700/year in 2015, 2016 and 2017 reflecting the international relevance of his research.
Prof Schmoll has established the structures for cooperative and multidisciplinary clinical cancer research in Germany for the past 30 years. He developed 30 cooperative clinical trial groups within the AIO for all tumor types that was the basis for the current acceptance of the AIO as one of the leading trial groups in the word and as the scientific and professional development of the younger generation.
Prof. Schmoll was also instrumental for the European recognition of “Med Onc” by forming a “political” coalition to change the voting of Germany in the EU. Within ESMO, he served in the Executive Board, founding chair of the Multidisciplinary Oncology Committee (MOC), and scientific chair of the Istanbul ESMO Congress 2006.
Pamela M. Klein, M.D.
-
Dr. Klein is Principal of PMK BioResearch offering advisory and strategic consulting for biotechnology and the pharmaceutical industry with deep expertise in oncology drug development. She serves as an advisor to Corporate Boards, CEO’s, The Investment Community and Management Teams. She is on the Board of Directors for Argenx (Netherlands) and an active member of numerous Scientific Advisor Boards ranging from early start-ups to more established companies. Previously, she was Chief
Medical Officer of Intellikine (acquired by Milleinium/Takeda), where she built the development organization bringing multiple early compounds from laboratory to clinic. Prior to this, Klein was Vice President, Development at Genentech where she led the development of a large portfolio of drugs including all the HER (Herceptin, Tarceva, Perjeta), Apoptosis (antibodies and small molecules) and Hematology compounds. Prior to Genentech, she was at The National Cancer Institute, where she obtained funding, built and served as Research Director of the NCI-Navy Breast Center.
She received her medical degree from Stritch School of Medicine, Loyola, completed a Medical Oncology Fellowship at the NCI serving as Chief Fellow and then completed an additional year in Cancer Genetics.
David Feigal, M.D.
-
Dr. Feigal is a Partner in NDA Partners. He spent 12 years with the US Food & Drug Administration (FDA) where he was Director, Center for Devices & Radiological Health (CDRH), Director, Division of Anti-infective & Antiviral Drug Products, Center for Drug Evaluation & Research (CDER), and Deputy Director, Center for Biologics Evaluation & Research (CBER). He is former Vice President of Global Regulatory Strategy, Amgen, and former Senior Vice President, Head of Global Regulatory and Global Safety Surveillance at Elan Corporation. Dr Feigal has more than 30 years of experience in drug development and regulation. Before joining the FDA, he worked for 10 years within the academic and hospital settings of the University of California in San Diego, San Francisco, and Davis.
He holds a BA from University of Minnesota, an MD from Stanford University and a Master of Public Health from the University of California, Berkeley.
Tanios Bekaii-Saab, M.D., F.A.C.P.
-
Tanios Bekaii-Saab, M.D., F.A.C.P. is a medical oncologist with a specific focus in gastrointestinal cancers.
Dr. Bekaii-Saab serves as the leader of the Gastrointestinal Cancer Program at the Mayo Clinic Cancer Center. He is also the medical director of the Cancer Clinical Research Office as well as the Vice Chair and Section Chief for Medical Oncology in the Department of Internal Medicine at the Mayo Clinic in Phoenix, Arizona, USA.
Dr. Bekaii-Saab conducts clinical and translational research focused on developing anti-cancer agents for patients with gastrointestinal cancers. Dr. Bekaii-Saab collaborates extensively with various scientists and industry partners to design and execute innovative clinical trials, including many first-in-human studies.
Dr. Bekaii-Saab’s research includes a large focus on the incorporation of agents that target the multiple facets of cancer, including genetic and epigenetic drivers, as well as the feeding microenvironment and the immune milieu. His work includes two recent discoveries as co-inventor of a molecule that targets cancer-related cachexia (AR-42) and an anti-PD-1 vaccine. His research has also led to the launch of a number of phase II and III clinical trials, including a recent trial with a cancer stem cell inhibitor (napabucasin) in pancreatic cancer, the development of an inhibitor of fibroblast growth factor receptor (FGFR) fusion genes in bile duct cancers, and a contribution to the pivotal study that led to the regulatory approval of nanoliposomal irinotecan for treating pancreatic cancer.
In addition to his clinical activities, Dr. Bekaii-Saab also serves as the chair for the cancer research consortium Academic and Community Cancer Research United (ACCRU) and is one of the leading clinician-scientists in the Alliance for Clinical Trials in Oncology, a National Cancer Institute (NCI)-supported cooperative research group.
György Bodoky, M.D. Ph.D.
-
Dr. Bodoky is the Head of the Oncology Department at Szent László Teaching Hospital in Budapest, Hungary.
Dr. Bodoky has conducted his investigations about the enteral and parenteral nutrition, the special research interests in this area have included the nutrition in pancreas disease, in liver coma and malignant diseases. The second area of his research includes the organization of Hungarian activities in clinical trials for gastrointestinal oncology, he has been and/or currently is the principal investigator in 132 studies, has been organizing 22 international conferences in the field of oncology and co-authored a number of peer-reviewed publications and textbooks both internationally and nationally.
Dr Bodoky is a member of the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the European Society for Parenteral and Enteral Nutrition (ESPEN). He is the Honorary President of the Hungarian Society of Clinical Oncology (HSCO). He is also a member of the Swiss Group for Clinical Cancer Research (SAKK) and a founding member of South-Eastern European Research Oncology Group (SEEROG). He was invited to be a member of the ARCAD Foundation (Academic Research on Cancer for Answers and Directions)
He is the chief editor “Journal of Clinical Oncology” (Hungarian edition) and a board member of the journal ”Journal of Metabolism and Nutrition” and founding editor of the journal “Rákgyógyítás”.
He received his medical degree from the Semmelweis Medical University Budapest, subsequently he obtained his PhD in 1992 and his Habilitation in 1998 from the Semmelweis Medical University.
Cathy Eng, M.D.
-
Dr Cathy Eng is a professor of Gastrointestinal Medical Oncology at Vanderbilt-Ingram Cancer Center (VICC), acting as co-leader of the VICC Gastrointestinal Cancer Research Program. She also oversees a large expansion in the clinical and research activities of the medical oncology gastrointestinal cancer disease group at Vanderbilt, as well as developing programs for adolescent and young adult (AYA) oncology services.
Previously, she has been with MD Anderson for 17 years, where she has served as the associate director of the Colorectal Center, chair of the Clinical Research Committee and chair of the Multidisciplinary Colorectal Cancer Tumor Board.
She holds numerous leadership roles in the field of gastrointestinal cancer. Dr Eng is serving her second term as National Cancer Institute (NCI) Rectal/Anal Cancer Task Force chair. She is the lead contact principal investigator for the NCI National Clinical Trials Network (NCTN) Leading Academic Participating Sites grant for two terms. She was recently elected co-chair of the Rectal/Anal Subcommittee for the Southwest Oncology Group (SWOG) and serves on the ECOG-ACRIN Cancer Research Group gastrointestinal committee. She has served as a volunteer and as a leader in numerous roles in the American Society of Clinical Oncology (ASCO) since 2002 and was acknowledged at the ASCO 2019 Annual Meeting for her years of volunteer service, dedication and commitment to ASCO with a Fellow of the American Society of Clinical Oncology (FASCO) distinction.
Dr Eng has been a principal investigator of innumerable national and international trials, including investigator-initiated trials, NCI-funded trials and major pharmaceutical-sponsored trials. Her work has led to numerous practice-changing outcomes, particularly with regard to the use of immunotherapy in metastatic anal cancer. Particularly due to her groundbreaking work in anal cancer, she served as the section leader for the Rare Cancers Subsection for the MD Anderson HPV Malignancies Moonshot Program.
Dr Eng received her medical degree from Hahnemann University School of Medicine in Philadelphia. She completed residency in internal medicine at Rush University Medical Center followed by a fellowship in hematology and oncology at the University of Chicago Medical Center.
Guillem Argiles, M.D. Ph.D.
-
Dr Guillem Argilés, has been a member of the Gastrointestinal Malignancies Division at the Vall d’Hebrón University Hospital since 2014. He began the early steps of his career focused on translational research by obtaining his Medical Oncology specialisation in 2011 under the supervision of Prof José Baselga, at the Vall d’Hebron University Hospital. In 2011 Dr Argilés joined the Phase 1 and Developmental Therapeutics Division of this institution for a fellowship stage in molecular therapeutics. During this period, he had the opportunity to be involved in the pre-clinical and early clinical studies that set the basis for further clinical development of some of the main molecularly-driven drugs currently emerging to clinical practice such as PI3K-MAPK, Wnt, Sonic Hedgehog, TGF-beta or Notch pathway inhibitors. Due to his interest in the field of metastatic colorectal cancer in 2014 Dr Argilés joined the Gastrointestinal Malignancies Division, at the Vall d’Hebrón University Hospital as staff member under the supervision of Prof Josep Tabernero.
Guillem Argilés’ career path seeks to expand the therapeutic universe of metastatic colorectal cancer by improving the acknowledgement of the biological processes behind these tumours. In this regard, he is currently involved in several translational lines of investigation like the development of new preclinical models that allow fast and reliable bedside-to-bench-and-back-to-the-bedside strategies for tailoring therapeutic strategies in colorectal cancer. Dr Argiles’ further fields of investigation are new immunotherapy approaches for non-hypermutant CRC patients and the identification of guiding biomarkers for new therapeutic interventions in CRC.